Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?

被引：49
|
作者：
Stoop, Jeroen N. [1 ]
Robinson, John H. [1 ]
Hilkens, Catharien M. U. [1 ]
机构：
[1] Newcastle Univ, Fac Med Sci, Musculoskeletal Res Grp, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2011年 / 70卷 / 09期
关键词：
COLLAGEN-INDUCED ARTHRITIS; REGULATORY T-CELLS; TH17; CELLS; IN-VIVO; TNF; RAPAMYCIN; INDUCTION; TOLERANCE; CARTILAGE; INTERLEUKIN-17;
D O I：
10.1136/ard.2011.151654
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
One of the therapeutic strategies under development for the treatment of rheumatoid arthritis is based on reinstating immune tolerance by vaccination with autologous dendritic cells with potent tolerogenic function. These tolerogenic dendritic cells (TolDC) can be generated ex vivo and have beneficial therapeutic effects in animal models of arthritis. Although experimental animal models have been instrumental in the development of this novel immunotherapeutic tool, several outstanding questions regarding the application of TolDC remain to be addressed. This paper reviews what has been learnt to date from studying the therapeutic potential of TolDC in animal models of arthritis and discusses issues relating to preventive versus curative effects of TolDC, the antigen specificity of TolDC therapy, the route, dose and frequency of TolDC administration and the safety of TolDC treatment. Lessons learnt from animal models will aid the design of clinical trials with TolDC.
引用
收藏
页码：1526 / 1533
页数：8
相关论文
共 50 条
  • [1] Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?
    Hilkens, C. M. U.
    Isaacs, J. D.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (02): : 148 - 157
  • [2] Tolerogenic dendritic cell therapy for rheumatoid arthritis
    Anderson, A. E.
    Swan, D. J.
    Harry, R. A.
    Sayers, B. L.
    Robinson, J. H.
    Isaacs, J. D.
    Hilkens, C. M.
    [J]. IMMUNOLOGY, 2008, 125 : 127 - 127
  • [3] Tolerogenic dendritic cell therapy for rheumatoid arthritis
    Anderson, Amy E.
    Sayers, Bethan L.
    Swan, David J.
    Isaacs, John D.
    Hilkens, Catharien M.
    [J]. RHEUMATOLOGY, 2008, 47 : II64 - II64
  • [4] Animal models of arthritis: What can we learn from the different mouse models?
    Joosten, L. A. B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 43 - 43
  • [5] WHAT CAN WE LEARN ABOUT RHEUMATOID-ARTHRITIS FROM ANIMAL-MODELS
    KLARESKOG, L
    [J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1989, 11 (03): : 315 - 333
  • [6] What can we learn from the synovium in early rheumatoid arthritis?
    A. Katrib
    H. P. McNeil
    P. P. Youssef
    [J]. Inflammation Research, 2002, 51 : 170 - 175
  • [7] What can we learn from the synovium in early rheumatoid arthritis?
    Katrib, A
    McNeil, HP
    Youssef, PP
    [J]. INFLAMMATION RESEARCH, 2002, 51 (04) : 170 - 175
  • [8] Sterol disorders: What can we learn from mouse models?
    Herman, Gail E.
    Cunningham, David
    Bir, Natalie
    Binkley, Laura
    Merkens, Louise
    Steiner, Robert
    [J]. MOLECULAR GENETICS AND METABOLISM, 2012, 105 (03) : 283 - 284
  • [9] Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
    Funda, David P.
    Palova-Jelinkova, Lenka
    Golias, Jaroslav
    Kroulikova, Zuzana
    Fajstova, Alena
    Hudcovic, Tomas
    Spisek, Radek
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [10] TOLEROGENIC DENDRITIC CELLS: A NOVEL THERAPY FOR RHEUMATOID ARTHRITIS
    Isaacs, John D.
    Anderson, Amy E.
    Stoop, Jeroen N.
    Harry, Rachel A.
    Swan, David J.
    Robinson, John H.
    Hilkens, Catharien M.
    [J]. RHEUMATOLOGY, 2009, 48 : I82 - I82
12345